Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 3/20 | 0.45 |
| ▸ | CTSB | P07858 | 3/20 | 0.45 |
| ▸ | PREP | P48147 | 1/20 | 0.44 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HRH2 | P25021 | 2/20 | 0.40 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23050302 | 0.90 | CTSK (0.53) | CTSKSMN1; SMN2USP2CTSLCTSB | |
| SCHEMBL7416847 | 0.87 | CTSK (0.52) | CTSKCTSLCTSBPREPCTSS | |
| SCHEMBL7414029 | 0.87 | CTSK (0.52) | CTSKCTSLCTSBPREPCTSS | |
| SCHEMBL16710005 | 0.86 | CTSK (0.51) | CTSKCTSLCTSBPREPCTSS | |
| SCHEMBL5441244 | 0.85 | SMN1; SMN2 (0.54) | CTSKSMN1; SMN2USP2CTSLCTSB | |
| SCHEMBL6164797 | 0.85 | SMN1; SMN2 (0.54) | CTSKSMN1; SMN2USP2CTSLCTSB | |
| SCHEMBL5451145 | 0.85 | SMN1; SMN2 (0.54) | CTSKSMN1; SMN2USP2CTSLCTSB | |
| SCHEMBL9512357 | 0.82 | CTSK (0.46) | CTSKSMN1; SMN2USP2CTSLCTSB | |
| SCHEMBL9512325 | 0.82 | CTSK (0.46) | CTSKSMN1; SMN2USP2CTSLCTSB | |
| SCHEMBL4702779 | 0.79 | SMN1; SMN2 (0.49) | SMN1; SMN2CTSSPKMKMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160002269-A1 | LANTHANIDE CLUSTERS AND METHODS OF USE THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2016-01-07 | — | — | US | disclosed |
| US-20160002269-A1 | LANTHANIDE CLUSTERS AND METHODS OF USE THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2016-01-07 | — | — | US | disclosed |
| WO-2014122664-A1 | LANTHANIDE CLUSTERS AND METHODS OF USE THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2014-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002269-A1 | LANTHANIDE CLUSTERS AND METHODS OF USE THEREOF | VAC14, LPXN, SLC39A7 | CTSK 3165/4885SMN1; SMN2 4125/4885USP2 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.